Open AccessSuccessful Management of Severe Hypercalcemia with Zoledronic Acid: A Report of Two Pediatric Cases
Author(s) -
Fatih Kilci,
Jeremy Jones,
Filiz Mine Çizmecioğlu-jones
Publication year - 2022
Publication title -
jcrpe
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.566
H-Index - 35
eISSN - 1308-5735
pISSN - 1308-5727
DOI - 10.4274/jcrpe.galenos.2022.2022-9-3
Subject(s) - zoledronic acid , medicine , etiology , malignancy , vitamin d and neurology , bisphosphonate , differential diagnosis , pediatrics , bone density conservation agents , osteoporosis , bone density , pathology
Severe hypercalcemia associated with vitamin D intoxication or malignancy in children is a rare and life-threatening condition. There is little published experience with Zoledronic acid in the treatment of pediatric severe hypercalcemia. Here, we present two pediatric cases of severe hypercalcemia, one due to vitamin D intoxication and the second to malignancy, in which Zoledronic acid was used as the first-line bisphosphonate in the treatment. While both cases responded well to a single dose of Zoledronic acid, the second case experienced hypocalcemia requiring calcium treatment after Zoledronic acid infusion. Our report shows that Zoledronic acid may be an effective option in the treatment of severe pediatric hypercalcemia, although patients should be followed closely after infusion due to the risk of hypocalcemia. We provide additional published evidence for the effectiveness of Zoledronic acid in correcting severe pediatric hypercalcemia and hope this will encourage future studies with larger numbers of patients.